Melphalan hydrochloride

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences: Wells Fargo Healthcare Conference on Thursday, September 10, 2026, in Boston, MA H.C. Wainwright 27 th Annual Global Investment Conference on Tuesday, September 15, 2026, in New York, NY About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver. Contacts Investor Relations Contact: ICR Healthcare investorrelations@delcath.com

SOUTH SAN FRANCISCO, CA / ACCESS Newswire / August 14, 2026 / CASI Pharmaceuticals, Inc. (OTCQB:CASIF), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with antibody-mediated rejection (AMR) in organ transplant and various autoimmune diseases, today reported business and financial results for the first half year ended June 30, 2026. "We remained focused on advancing the development of our lead program, CID-103," said Dr. Wei-Wu He, Executive Chairman and Principal Executive Officer of CASI. "We dosed the first patient in the Phase 1/2 trial evaluating the safety and tolerability of CID-103 in adult patients with active and chronic active renal allograft antibody-mediated rejection (AMR) in China. We also completed the enrollment of Part A (the dose-escalation part) of our ongoing Phase 1/2 study in immune thrombocytopenia (ITP), with the maximum tested dose of 1,200 mg." Business Highlights Program Updates and Upcoming Milestones CID-103 for Antibody-Mediated Rejection (AMR) for Renal Allografts Approval of clinical trial application by China NMPA for Phase 1/2 study First patient dosed in Phase 1/2 study in China CID-103 for Immune Thrombocytopenia (ITP) Completed enrollment in Part A, the dose-escalation part, of the ongoing Phase 1/2 study, with the maximum tested dose of 1,200 mg Corporate Completed $15 million convertible note financing pursuant to certain convertible note purchase agreement with ETP Global III Fund LP, a partnership controlled by Dr. Wei-Wu He Dr. Wei-Wu He, Ph.D., assumed the role of the Company's principal executive officer while continuing to serve as Executive Chairman Subsequent to quarter-end, received a favorable final award in the Juventas arbitration, pursuant to which the tribunal rejected all of Juventas's allegations of breach, determined that Juventas had wrongfully terminated the relevant agreements, and awarded the Company amounts totaling well over RMB 100 million Entered into a Settlement Agreement with Acrotech Biopharma Inc., pursuant to which the prior purported termination of the EVOMELA ® license and related agreements was rescinded and the agreements remain in full force and effect, subject to certain revisions Ordinary shares began to be quoted for trading on the OTCQB market under the ticker CASIF First Half 2026 Financial Highlights Revenues for the first half of 2026 were $9.8 million, representing a 5.8% decrease compared to $10.4 million in the same period last year. The decline in revenue was primarily attributable to the product transition from EVOMELA ® to the locally manufactured MAFALAN ® , which remains in its market‑expansion phase. Cost of revenue for the first half of 2026 was $2.2 million, representing a 53.2% decrease compared to $4.7 million in the same period last year. The decrease was mainly attributable to lower unit cost for MAFALAN ® than that of EVOMELA ® . Research and development expenses for the first half of 2026 were $2.3 million, representing a 37.8% decrease compared to $3.7 million in the same period last year. The decrease was mainly attributable to decreased clinical studies costs for our pipeline products, as well as decreased labor cost. General and administrative expenses for the first half of 2026 were $14.3 million, representing a 3.6% increase compared to $13.8 million in the same period last year. The increase was mainly attributable to increased legal fees, partially offset by decreased labor cost. Selling and marketing expenses for the first half of 2026 were $7.5 million, representing an 18.5% decrease compared to $9.2 million in the same period last year. The decrease was mainly attributable to decreased labor cost and decreased travel and conference fees. Net loss for the first half of 2026 was $20.0 million, compared to $24.1 million in the same period last year. As of June 30, 2026, cash and cash equivalents of the Company was $3.8 million, compared to $5.6 million as of December 31, 2025. As of June 30, 2026, total outstanding shares of the Company were 20,555,873. Nasdaq Delisting and OTCQB Quotation On February 23, 2026, the Company received a determination letter from the Hearings Panel of The Nasdaq Stock Market notifying the Company that the Panel had determined to delist the Company's securities due to the Company's failure to satisfy Nasdaq's continued listing requirements. As a result, trading in the Company's securities was suspended at the opening of business on February 26, 2026. On June 23, 2026, Nasdaq filed Form 25 in relation to such delisting decision. On April 14, 2026, the Company's ordinary shares began to be quoted for trading on the OTCQB market under the ticker CASIF. About CASI Pharmaceuticals CASI Pharmaceuticals, Inc. is a public biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. CID-103 is a fully human IgG1, potentially best-in-class, clinical-stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging preclinical efficacy and clinical safety pro to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) in the U.S. In parallel, CASI is actively recruiting and dosing patients in two ongoing Phase 1/2 studies in immune thrombocytopenia (ITP) and active and chronic active renal allograft antibody-mediated rejection. More information on CASI is available at . Forward-Looking Statements This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: uncertainties related to the going-private proposal made by Dr. Wei-Wu He; uncertainties related to the possibility that the transaction for the divestiture of certain assets in China (the "Transaction") will not occur as planned if events arise that result in the termination of the Equity and Assets Transfer Agreement, or if one or more of the various closing conditions to the Transaction are not satisfied or waived; the possibility that our plan with respect to our business operations after the consummation of the Transaction can be implemented successfully; our recurring operating losses have raised substantial doubt regarding our ability to continue as a going concern; the volatility in the market price of our ordinary shares; the risk of substantial dilution of existing shareholders in future share issuances; the difficulty of executing our business strategy on a global basis including China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; legal or regulatory developments in China that adversely affect our ability to operate in China; our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency, PRC National Medical Products Administration, or other regulatory authorities; our inability to receive approval for renewal of license of our existing products; the risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the risks associated with our product candidates, and the risks associated with our other early-stage products under development; the risk that results in preclinical and clinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; our ability to protect our intellectual property rights; the lack of success in the clinical development of any of our products; and our dependence on third parties; uncertainties regarding the timing, enforcement and collection of the amounts awarded to the Company in the Juventas arbitration; risks associated with the Company's obligations under the Settlement Agreement with Acrotech, including applicable minimum purchase obligations; the risk related to the Company's ongoing development of and regulatory application for CID-103 with respect to the treatment of antibody-mediated rejection for organ transplant and the license arrangements of CID-103; risks relating to interests of our largest shareholder and our Chairman that differ from our other shareholders; and risks related to the development of a new manufacturing facility by CASI Pharmaceuticals (Wuxi) Co., Ltd. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided herein is as of the date of this announcement, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein. EVOMELA ® and FOLOTYN ® are proprietary to Acrotech Biopharma Inc. and its affiliates. COMPANY CONTACT: Deanna Qian +86 6561 8789 deannaq@casi.cn Financial Table Follows CASI Pharmaceuticals, Inc. Unaudited Condensed Consolidated Balance Sheets (In USD thousands, except share and per share data) June 30, 2026 December 31, 2025 ASSETS Current assets: Cash and cash equivalents $ 3,765 $ 5,632 Accounts receivable, net of nil expected credit loss 3,437 4,092 Inventories 1,837 1,598 Prepaid expenses and other 984 2,135 Total current assets 10,023 13,457 Long-term investments 1,716 1,716 Property, plant and equipment, net 6,570 6,968 Intangible assets, net 214 221 Right of use assets 1,860 2,548 Other assets 680 740 Total assets $ 21,063 $ 25,650 LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY Current liabilities: Accounts payable $ 1,065 $ 1,065 Bank borrowings 1,474 1,001 Accrued and other current liabilities 25,055 24,171 Convertible notes due to a related party 19,243 4,243 Current portion of long-term borrowing 19,780 19,190 Total current liabilities 66,617 49,670 Other liabilities 12,712 13,262 Total liabilities 79,329 62,932 Commitments and contingencies Shareholders' (deficit) equity: Ordinary shares 2 2 Treasury shares (9,604 ) (9,604 ) Additional paid-in capital 722,308 722,238 Accumulated other comprehensive loss (2,803 ) (1,785 ) Accumulated deficit (768,169 ) (748,133 ) Total shareholders' (deficit) equity (58,266 ) (37,282 ) Total liabilities and shareholders' (deficit) equity $ 21,063 $ 25,650 CASI Pharmaceuticals, Inc. Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share data) Six months ended June 30, 2026 June 30, 2025 Revenues 9,817 10,415 Costs of revenues (2,154 ) (4,738 ) Gross profit 7,663 5,677 Operating income (expenses): Research and development (2,330 ) (3,660 ) General and administrative (14,265 ) (13,782 ) Selling and marketing (7,506 ) (9,183 ) Foreign exchange gain (loss) 355 (561 ) Total operating expense (23,746 ) (27,186 ) Loss from operations (16,083 ) (21,509 ) Non-operating income (expense): Interest income 5 122 Interest expense (1,342 ) (441 ) Other income 3 35 Changes in fair value of investments - (158 ) Loss before income tax expense and share of net loss in an equity investee (17,417 ) (21,951 ) Income tax benefit - - Share of net loss in an equity investee (2,616 ) (2,174 ) Net loss (20,033 ) (24,125 ) Weighted average number of ordinary shares outstanding (basic and diluted) 20,555,873 15,499,318 Net loss per share (basic and diluted) (0.97 ) (1.56 ) Comprehensive loss: Net loss (20,033 ) (24,125 ) Foreign currency translation adjustment (1,018 ) (466 ) Total comprehensive loss (21,051 ) (24,591 ) Less: comprehensive loss attributable to redeemable noncontrolling interest - - Comprehensive loss attributable to ordinary shareholders (21,051 ) (24,591 ) SOURCE: CASI Pharmaceuticals View the original press release on ACCESS Newswire